With echoes of Theranos, Truvian Sciences revives the dream of low-cost, accessible blood tests – TechCrunch

A little over a year after the dissolution of the once high-flying blood testing startup Theranos, another startup has raised more than $27 million to breathe new life into the vision of bringing low-cost blood tests to point-of-care medical facilities. Unlike Theranos, Truvian Sciences is not claiming that most of its blood tests do not need clearance from the U.S. Food and Drug Administration,